APA (7th ed.) Citation

D, A., M, O., WA, R., D, C., J, R., JE, G., . . . A, A. (2025). Author's Reply to Peronard and Mayntz: "SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect". American journal of cardiovascular drugs : drugs, devices, and other interventions, 25(1), 131. https://doi.org/10.1007/s40256-024-00707-8

Chicago Style (17th ed.) Citation

D, Aristizábal-Colorado, Ocampo-Posada M, Rivera-Martínez WA, Corredor-Rengifo D, Rico-Fontalvo J, Gómez-Mesa JE, Duque-Ossman JJ, and Abreu-Lomba A. "Author's Reply to Peronard and Mayntz: "SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect"." American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions 25, no. 1 (2025): 131. https://doi.org/10.1007/s40256-024-00707-8.

MLA (9th ed.) Citation

D, Aristizábal-Colorado, et al. "Author's Reply to Peronard and Mayntz: "SGLT2 Inhibitors, and How They Work Beyond the Glucosuric Effect"." American Journal of Cardiovascular Drugs : Drugs, Devices, and Other Interventions, vol. 25, no. 1, 2025, p. 131, https://doi.org/10.1007/s40256-024-00707-8.